These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
866 related articles for article (PubMed ID: 31234870)
1. ARL3 is downregulated and acts as a prognostic biomarker in glioma. Wang Y; Zhao W; Liu X; Guan G; Zhuang M J Transl Med; 2019 Jun; 17(1):210. PubMed ID: 31234870 [TBL] [Abstract][Full Text] [Related]
2. Qu S; Liu J; Wang H Front Immunol; 2021; 12():648416. PubMed ID: 33889156 [TBL] [Abstract][Full Text] [Related]
3. Systematic identification, development, and validation of prognostic biomarkers involving the tumor-immune microenvironment for glioblastoma. Zhao B; Wang Y; Wang Y; Chen W; Liu PH; Kong Z; Dai C; Wang Y; Ma W J Cell Physiol; 2021 Jan; 236(1):507-522. PubMed ID: 32572951 [TBL] [Abstract][Full Text] [Related]
4. Integrative Analysis of Neuregulin Family Members-Related Tumor Microenvironment for Predicting the Prognosis in Gliomas. Zhao WJ; Ou GY; Lin WW Front Immunol; 2021; 12():682415. PubMed ID: 34054873 [TBL] [Abstract][Full Text] [Related]
5. An Immune-Related Signature for Predicting the Prognosis of Lower-Grade Gliomas. Zhang H; Li X; Li Y; Chen B; Zong Z; Shen L Front Immunol; 2020; 11():603341. PubMed ID: 33363544 [TBL] [Abstract][Full Text] [Related]
6. Ferroptosis-related gene signature correlates with the tumor immune features and predicts the prognosis of glioma patients. Hu Y; Tu Z; Lei K; Huang K; Zhu X Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34726238 [TBL] [Abstract][Full Text] [Related]
7. Machine learning-based identification of a cell death-related signature associated with prognosis and immune infiltration in glioma. Zhou Q; Wu F; Zhang W; Guo Y; Jiang X; Yan X; Ke Y J Cell Mol Med; 2024 Jun; 28(11):e18463. PubMed ID: 38847472 [TBL] [Abstract][Full Text] [Related]
8. SYT16 is a prognostic biomarker and correlated with immune infiltrates in glioma: A study based on TCGA data. Chen J; Wang Z; Wang W; Ren S; Xue J; Zhong L; Jiang T; Wei H; Zhang C Int Immunopharmacol; 2020 Jul; 84():106490. PubMed ID: 32289666 [TBL] [Abstract][Full Text] [Related]
9. Investigation of Genetic Determinants of Glioma Immune Phenotype by Integrative Immunogenomic Scale Analysis. Zhao B; Wang Y; Wang Y; Dai C; Wang Y; Ma W Front Immunol; 2021; 12():557994. PubMed ID: 34220791 [TBL] [Abstract][Full Text] [Related]
10. CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry. Hu M; Li Z; Qiu J; Zhang R; Feng J; Hu G; Ren J Bioengineered; 2021 Dec; 12(1):5996-6009. PubMed ID: 34494924 [TBL] [Abstract][Full Text] [Related]
11. Prognostic Gene Expression Signature in Patients With Distinct Glioma Grades. Ait Ssi S; Chraa D; El Azhary K; Sahraoui S; Olive D; Badou A Front Immunol; 2021; 12():685213. PubMed ID: 34539626 [TBL] [Abstract][Full Text] [Related]
12. Comprehensive exploration of tumor mutational burden and immune infiltration in diffuse glioma. Kang K; Xie F; Wu Y; Wang Z; Wang L; Long J; Lian X; Zhang F Int Immunopharmacol; 2021 Jul; 96():107610. PubMed ID: 33848908 [TBL] [Abstract][Full Text] [Related]
13. A cuproptosis-based prognostic model for predicting survival in low-grade glioma. Zhao Z; Ma Y; Liu Y; Chen Z; Zheng J Aging (Albany NY); 2024 May; 16(10):8697-8716. PubMed ID: 38738989 [TBL] [Abstract][Full Text] [Related]
14. Grade II/III Glioma Microenvironment Mining and Its Prognostic Merit. Chen J; Hou C; Wang P; Yang Y; Zhou D World Neurosurg; 2019 Dec; 132():e76-e88. PubMed ID: 31518750 [TBL] [Abstract][Full Text] [Related]
15. SCAMP4 is a novel prognostic marker and correlated with the tumor progression and immune infiltration in glioma. Ge X; Wang Z; Jiang R; Ren S; Wang W; Wu B; Zhang Y; Liu Q Int J Biochem Cell Biol; 2021 Oct; 139():106054. PubMed ID: 34390854 [TBL] [Abstract][Full Text] [Related]
16. Identification of a five B cell-associated gene prognostic and predictive signature for advanced glioma patients harboring immunosuppressive subtype preference. Zhang C; Li J; Wang H; Song SW Oncotarget; 2016 Nov; 7(45):73971-73983. PubMed ID: 27738332 [TBL] [Abstract][Full Text] [Related]
17. RAB38 confers a poor prognosis, associated with malignant progression and subtype preference in glioma. Wang H; Jiang C Oncol Rep; 2013 Nov; 30(5):2350-6. PubMed ID: 24026199 [TBL] [Abstract][Full Text] [Related]
18. MXRA5 Is a Novel Immune-Related Biomarker That Predicts Poor Prognosis in Glioma. Sun JZ; Zhang JH; Li JB; Yuan F; Tong LQ; Wang XY; Chen LL; Fan XG; Zhang YM; Ren X; Zhang C; Yu SP; Yang XJ Dis Markers; 2021; 2021():6680883. PubMed ID: 34211612 [TBL] [Abstract][Full Text] [Related]
19. Identification of SEC61G as a Novel Prognostic Marker for Predicting Survival and Response to Therapies in Patients with Glioblastoma. Liu B; Liu J; Liao Y; Jin C; Zhang Z; Zhao J; Liu K; Huang H; Cao H; Cheng Q Med Sci Monit; 2019 May; 25():3624-3635. PubMed ID: 31094363 [TBL] [Abstract][Full Text] [Related]
20. Cuproptosis-related gene-located DNA methylation in lower-grade glioma: Prognosis and tumor microenvironment. Zhu L; Yuan F; Wang X; Zhu R; Guo W Cancer Biomark; 2024; 40(2):185-198. PubMed ID: 38578883 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]